Needham & Company downgraded Regado Biosciences (NASDAQ: RGDO) from Buy to Hold after enrollment in the Phase III REGULATE-PCI trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE